FLAG Therapeutics, Inc., an early-stage oncology company based in Raleigh, North Carolina, focuses on developing therapies using two novel classes of small molecule, water-soluble drugs. In vivo studies indicate that its antiangiogenic/anti-tubulin (AA/AT) compounds and folate-targeted anti-cancer (FTAC) compounds have the potential to treat multiple cancer types more safely and effectively than conventional therapies. Notably, FLAG Therapeutics has secured exclusive worldwide rights to these compounds from Duquesne University. Founded in 2013, the company operates in the Health and Wellness and Pharmaceutical industries. As of now, there is no available information regarding the last investment or the investors associated with FLAG Therapeutics.
There is no investment information
No recent news or press coverage available for FLAG Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.